Close menu




December 14th, 2020 | 12:54 CET

TUI, Blackrock Gold, ThyssenKrupp - This news will move the share prices

  • Investments
Photo credits: Blackrock Gold Corp.

Very different developments have been reported by the Companies mentioned in recent days. In our opinion, this news will also determine the direction of prices in the near future. How should traders and investors position themselves? We took a closer look at these shares.

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: CA09258M1014 , DE0007500001 , DE000TUAG000

Table of contents:


    TUI - Further price losses to be expected

    On December 2, 2020, the travel group reported that it had reached an agreement with a consortium of banks, KfW and the Economic Stabilization Fund on a further financing package worth EUR 1.8 billion. In retrospect, this agreement came just in time before the upcoming lockdown.

    Last Thursday, the Group reported on the fiscal year that ended on September 30, 2020. The figures presented a devastating picture. Revenue slumped by 58%; guest numbers fell by as much as 62%. Operationally, a loss of EUR 3 billion was incurred. The Group's plans to streamline its operations in the future and raise its annual savings targets from EUR 300 to EUR 400 million failed to excite many market participants given the losses incurred and the intangible change processes.

    Analysts downgraded the TUI share in succession. The Swiss UBS was particularly negative. The analyst in charge put the share up for sale with a price target of 110 pence (equivalent to EUR 1.20). The share has already lost almost a quarter of its value since the beginning of December. Now that several factors are intensifying negatively (lockdown, low figures and analyst downgrades), the TUI share is likely to head further south. The EUR 3 area has marked the end of the downward movement several times in recent months.

    Blackrock Gold - 2021 will be exciting

    The exploration Company Blackrock Gold is focusing its efforts exclusively on its two projects, Silver Cloud and Tonopah, in the US state of Nevada. The goal is to discover new, economic gold and silver deposits along established trends or zones of mineralization.

    In early December 2020, the Company reported drill results from the DPB zone of the Tonopah project. Several intercepts of high-grade mineralization were encountered, confirming the Company's geological model. Blackrock Gold also announced its intention to establish a resource definition by the end of 2021. Additional drilling programs must be run for this.

    After a consolidation that has been ongoing since the summer, the Company is currently valued at CAD 65 million. Rising precious metal prices and, in particular, the newsflow from new drilling programs should boost the share price again next year. Traditionally, the month of December offers good entry opportunities, especially in Canada, as investors exit for tax reasons. It is not uncommon to see a significant price increase already after the turn of the year.

    ThyssenKrupp - no state aid

    The Group already initiated the strategic realignment in May 2019. But as is so often the case, transformation processes prove to be more protracted than expected and put investors' patience to the test.

    The focus is currently on the Group's ailing steel division. On Friday thyssenkrupp reported that the Group was rejecting a state investment. With its strict conditions, the economic stabilization fund is not the right vehicle for restructuring the steel business with equity. The Company now wants to decide by next March on how to proceed with the steel business. If the Group continues with the business, this will entail massive cost reductions and job cuts. Another option is to sell the business. There is currently an offer from the British Liberty Steel.

    The stock has recovered significantly from the lows of recent months. The news situation, sentiment and many question marks over the future of the steel business argue for continued weaker share prices.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read